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Summary A study on the in vitro sensitivity of tumour cells from patients with ovarian cancer has been
carried out in parallel with a clinical study designed to evaluate the role of high-dose cis-platinum (CIS) as
first-line chemotherapy. A total of 50 samples from 102 patients have been successfully cultured and screened
for in vitro chemosensitivity to 7 drugs, including CIS. The malignant nature of cells growing in culture was
confirmed using a combination of karyology, morphology and immunohistochemical staining with HMFG2.
Tumours were graded as sensitive (<40% of control 3H-leucine incorporation), intermediate (41-60% of
control) or resistant (>61% ofcontrol) to CIS.
Correlation of in vitro sensitivity to cis-platinum with clinical response to cis-platinum assessed using CT
scan and second-look laparotomy, showed positive correlation in 9/11 (89%) patients (8 =S/S; 1 =R/R);
positive correlation between in vitro sensitivity to phosphoramide mustard and clinical response was also
found in 4/6 patients receiving cyclophosphamide (3 =S/S; 1=R/R). All patients with sensitive tumours
showed a clinical response to cis-platinum.
Comparison of cis-platinum sensitivity with sensitivity to phosphoramide mustard and melphalan showed
that some tumours were sensitive only to cis-platinum; resistance to cis-platinum and sensitivity to
phosphoramide mustard/melphalan was an infrequent occurrence. Some tumours which were resistant to cis-
platinum showed sensitivity to adriamycin and bleomycin, particularly those from untreated patients.
Sensitivity to 5-fluorouracil and resistance to cis-platinum was found in approximately equal proportions of
tumours in both the treated and untreated groups.
Although response rates of approximately 50% have been
achieved with alkylating agents in the treatment of ovarian
cancer, survival times have not been significantly prolonged
in this disease which still represents the leading cause of
death from gynaecological cancer in the UK. New chemo-
therapeutic regimes are under continual evaluation and the
finding that cis-platinum II diammine dichloride (CIS) could
produce response rates of 30-40% in heavily pre-treated
patients (Wiltshaw & Kroner, 1976; Bruckner et al., 1978)
argued for its trial as a first-line drug in the treatment of
ovarian cancer. At the time this study was started there were
no previous reports which described the use of high dose
CIS (1OOmgm-2) in untreated patients with ovarian
carcinoma, and a clinical trial was initiated to evaluate this
regime. In conjunction with this, a laboratory study was set
up to evaluate the in vitro response of tumour cells from trial
patients to CIS. The patient group was potentially well
suited to such a study because (a) most patients received a
single drug, (b) there was surgical evidence of tumour
burden at the onset of chemotherapy and (c) stringent
response criteria including the use of computerised
tomography and second look laparotomies (2LL) were used
to evaluate response.
Results obtained with in vitro chemosensitivity testing of
human ovarian tumour cells growing as a monolayer in
microtitration plates have previously been described (Wilson
& Neal, 1981). More recent studies using cell lines have
shown that clonogenic assays and the microtitration assay
give similar chemosensitivity results in spite of their intrinsic
differences (Wilson et al., 1984). The microtitration assay
was chosen for this study in preference to the clonogenic
assay used by other groups, (e.g. Hamburger et al., 1978;
Courtenay & Mills, 1978; Von Hoff et al., 1983; Simmonds
& McDonald, 1984) because of the low cell requirement
which offers the facility of multiple drug screening over
several drug concentrations.
The aims of the study were (i) to compare in vitro
sensitivity to CIS with in vivo response to single agent
therapy with this drug; (ii) to evaluate in vitro sensitivity to
CIS after completion of chemotherapy and (iii) to compare
in vitro sensitivity to CIS with sensitivity to other drugs in
tumours from untreated and treated patients. Attention has
also been focussed on the critical aspects specific to the use
of monolayer cultures, including cell identification and the
effect of stromal cell contamination on chemosensitivity
profiles.
Materials and methods
Patients
Tumour samples were obtained from 72 patients in
Birmingham and 30 patients in Manchester, all with histo-
logically proven ovarian malignancy. Specimens comprising
solid tumours, ascitic and pleural fluids and peritoneal
washings were obtained from staging laparotomies, second
look laparotomies and paracenteses.
Chemotherapy
Birmingham patients were mainly treated with 5 courses of
100mgm-2 CIS, given as a bolus i.v. injection at three
weekly intervals; a separate patient group was treated with a
combination of CIS (50mgm-2), adriamycin - ADM
(50mg) and cyclophosphamide - CYM (1 gm) (CAP). In
Manchester, treatment protocols comprised either 3 courses
of CIS (1OOmgm-2) at three weekly intervals with 15mg
bleomycin - BLM administered i.v. at weekly intervals,
followed by consolidation with at least 5 courses of CYM
(1 gm-2), or CYM (1 gm-2) at 3 weekly intervals for 10
courses; a separate patient group received CIS (80mgm-2)
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and ADM (60mgm-2) for 6 courses at 3 to 4 weekly
intervals.
Response evaluation
A complete clinical response was defined by the
disappearance of all signs of disease, and a partial response
by an approximate reduction of 50% in tumour masses.
Computerised tomography was used to assist in clinical
evaluation. A complete surgical response was defined as the
disappearance of all macroscopic disease at second look
laparotomy, and a partial surgical response as a measured
reduction of 50% in the largest mass present at staging
laparotomy.
Cellpreparation
Methods which have been described previously (Wilson &
Neal, 1981) were used with the following modifications:
disaggregation of solid tumour tissue was carried out using
2-4mgml -1 collagenase (Worthington) and 50pgml -1
DNA-ase (Miles Chemical Co.) in growth medium - (GM -
Dulbecco's Modification of Eagles Medium supplemented
with 20% foetal calf serum, 1 mm glutamine, 1 mm sodium
pyruvate, 20IU1 -1 insulin, 20IUml -1 penicillin, 20pgml-1
streptomycin and 3.7g1-1 sodium bicarbonate). After
washing, disaggregated cells were adjusted to a final
concentration of 105 viable cellsml-1 in GM. Viabilities of
>90% were routinely obtained. Flat bottomed micro-
titration plates (Nunc) were seeded with 200pl of the cell
suspension per well, and were then incubated at 37°C in an
atmosphere of 95% air/5% CO2. In some specimens cultures
were initiated in 75cm2 plastic culture flasks and passage I
cells were used for the assay. Cells from some tumours
would not adhere to plastic and when this occurred the
plates were centrifuged at -200g for 10min prior to the
removal of medium at each stage of the assay.
Cell identification
The presence of tumour cells in the original cell suspension
was confirmed by microscopic examination of smears stained
with haematoxylin and eosin; histological diagnosis of
ovarian malignancy was confirmed in the biopsy specimens.
Slide chambers (Labtek) were routinely set up for all samples
and used for the identification of cell types growing in the
monolayer. Cultures were fixed in acetic acid:methanol
(1:3 i.v./v) and stained with haematoxylin and eosin.
Conventional criteria as defined in the literature (loachim
et al., 1974; Whitehead & Hughes, 1975; Mouriquand et al.,
1978) were used to identify putative mesothelial cells,
fibroblasts and tumour cells. Additionally, the same slide
chamber cultures were destained with acid-alcohol and
alcohol and subsequently used for immunohistochemical
staining with OC125 (Bast et al., 1981) and HMFG2
(Taylor-Papadimitriou et al., 1981), using an indirect
immunoperoxidase technique to confirm the presence of
epithelial cells. Chromosome preparations were also made of
some cultures using routine techniques.
Drugs
The following drugs were tested: adriamycin - ADM
(Farmitalia, Carlo Erba Ltd.), bleomycin - BLM (Lundbeck
Ltd.), cis-platinum II diammine dichloride - CIS (NCI,
Bethesda), 5-fluorouracil - 5-FU (Roche Products Ltd.),
melphalan - MEL (Burroughs Wellcome Ltd.) and
vinblastine - VLB (Velbe, Eli Lilly). The concentrations used
were selected to include achievable plasma levels (Alberts &
Chen, 1980). ADM was tested at 2, 0.2 and 0.02ygml-1,
VLB at 1, 0.1 and 0.01pgml-I and all other compounds at
10, 1 and 0.1pgml-1. In 9 tumour cultures CIS was tested
over an extended concentration range (10, 5, 3, 2, 1,
0.1 pgml-1). MEL was dissolved in dimethyl sulphoxide
(DMSO) prior to dilution in GM, and a solvent control at
the corresponding dilutions was routinely included. Other
compounds were dissolved in GM and all solutions were
made up immediately before use, using aseptic technique
without filtration.
Cytotoxic determination
Drugs were added 24-48h after culture initiation and were
left in situ for 48h. Following a 24h recovery period in GM
only the amount of 3H-leucine incorporated into protein was
determined using previously described methods (Freshney et
al., 1975). Results were expressed as a percentage of the
mean control values of 3H-leucine incorporation. Standard
deviations of the test means (n=3) were routinely < + 10%
of the control mean (n=3), although higher values
occasionally occurred. Reproducibility of the assay was
assessed by comparing results from 25 different assays for
chemosensitivity to CIS, using an ovarian tumour cell line,
OAW 42 (passage 30-66). The mean percentage of control
values+standard deviation were 1.2% +0.8%, 26% +15%
and 72% +23% at 10, 1 and 0.1 pgml 1 respectively.
Stromal cell contamination
Pure fibroblast or mesothelial cell cultures were obtained
from 4 samples. The chemosensitivity profiles of these
normal cell populations were measured for comparison with
the tumour cells. In addition the effect of combining
different proportions of both mesothelial cells and fibroblasts
with the cell line OAW 42 on the measured chemosensitivity
was determined. Proportions of 10%, 30%, 50%, 70% and
90% stromal cells with tumour cells were used as the initial
cell innocula in the microtitration plate assay.
Results
In Birmingham, 104 samples were obtained from 72 patients
with ovarian malignancy. Culture of 92 samples was
attempted and successful growth with <30% stromal cell
contamination was achieved with 35 samples (39%) from 27
patients. These included multiple sites from 4 patients (n=3,
n=4, n=2, n=2) and repeat samples from one patient
(n=2). Of the tumours which grew successfully 26 were from
untreated patients, (5 ascites, 21 solid tumours) and 9 from
treated patients, including relapse and second-look
laparotomies (4 ascites, 5 solid tumours). In Manchester, 38
samples were obtained from 30 patients and successful
growth was achieved with 15 (39%). Of these 15 samples, 10
were from relapsed patients (10 ascites) and 5 were from
untreated patients (2 solid tumours, 2 ascites, 1 pleural
fluid). Repeat samples were grown successfully from one
patient (n=3). Reasons for the failure to obtain adequate
cultures with some samples included excessive stromal cell
growth (>30%), inadequate growth of tumour cells, paucity
of tumour sample, nature of tumour sample (e.g., necrotic,
cystic, fibrotic), absence or very low yield of tumour cells in
fluids and infection.
Cell identification
Preliminary staining of freshly fixed slide chamber cultures
of 3 ovarian tumour cell lines, 8 mesothelial cell cultures and
2 fibroblast cultures was performed with OC 125 and
HMFG2. Mesothelial cells and fibroblasts were weakly
reactive with OC 125 whereas HMFG2 reacted only with the
ovarian tumour cell lines. Subsequent staining of slide
cultures for retrospective confirmation of cell type was,
therefore, done with HMFG2. A total of 34 specimens were
stained which, according to morphological criteria, included
9 stromal cell cultures, 7 pure tumour cell cultures and 18
mixed cell cultures containing varying proportions of normal
cells and tumour cells. No stromal cell cultures stained with
HMFG2 and putative tumour cells stained in all but 3In vitro CHEMOSENSITIVITY TO cis-PLATINUM 765
samples (64, 65, 11 M). Karyotyping of samples 64 and 65
confirmed the malignant nature of these cells. In sample 64 a
mode of 44 48 was obtained in 52/52 spreads, all of which
contained abnormal chromosomes. Samples 65 showed a
mode of 42-46 in 64/88 spreads with chromosomal
abnormalities which clearly distinguished them from the
normal cells comprising 26% of the total population. Sample
11 M was a mixed homologous mesenchymal sarcoma of the
ovary which showed a bizarre morphology without
displaying any features typical of epithelial cells. The
proportion of stromal cells present in cultures was thus
based on a semi-quantitative assessment using morphology,
HMFG2 staining and karyology.
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Effect ofstromal cells on the chemosensitivity ofOAW 42
Four pure stromal cell cultures (2 fibroblast, 2 mesothelial)
were screened for chemosensitivity. The results summarized
in Table I show that these populations were comparatively
chemoresistant. The effect of introducing increasing
proportions of normal cells into the tumour cell population
(OAW 42) on sensitivity to CIS is shown in Figure la,b for
fibroblasts and mesothelial cells. It is apparent that the
decrease in sensitivity to CIS was proportional to the
increase in normal cell contamination. At 30%
contamination the decrease in sensitivity was 7% at
1 ,gml-1 of CIS, and this was within the experimental
variation (see Materials and methods) of the assay, and
contrasts with a decrease in sensitivity of 30% at the 50%
contamination level. Therefore, only those cultures which
showed <30% stromal cell contamination have been used in
the comparison between clinical data and in vitro data. The
tumour cell cultures exhibited wide variations (which
exceeded the experimental variation) in sensitivity to the
different drugs tested and confirmed the earlier findings with
the assay (Wilson & Neal, 1981) that in vitro chemo-
sensitivity reflected in vivo response rates to single agent
chemotherapy.
Table I Sensitivity to chemotherapeutic agents of fibroblasts and
mesothelial cells from solid carcinoma and malignant effusions
Fibroblasts Mesothelial cells
ConcN
igml-l 7a 53 53 16
ADM 2.0 lb 104 48 4
0.2 74 103 79 76
0.02 98 100 89 70
CIS 10.0 27 <1 1 2
1.0 92 80 69 74
0.1 105 89 87 77
PM 10.0 123 99 74 -
1.0 117 98 89 -
0.1 114 92 101 -
MEL 10.0 50 - 73 -
1.0 103 - 86 -
0.1 168 - 97 -
aNormal cell cultures were tested from patients 7, 53 and
Passage 1 cells were used for 7 and 16, and passage 3 for
bPercent ofcontrol 3H-leucine incorporation.
16.
53;
5-FU, VLB, ADM, BLM, PM
Dose response curves for these drugs were similar to those
presented previously (Wilson & Neal, 1981) and will not,
therefore be shown for individual patients. Data from the
curves are summarised in Table II with treated and
untreated patients shown separately. The largest variation in
sensitivity between tumours from individual patients
occurred at 10pgml-1 of PM, and for 5-FU, VLB, ADM
and BLM there was considerable variation at the two higher
100
50
0
100
50
0
a
b
Cis platinum ,ug ml-1
Figure 1 The effect of introducing varying proportions of
fibroblasts (A) and mesothelial cells (B) on the measured dose-
response ofan ovarian cell line (OAW 42) to cis-platinum.
* - 100% stromal cells (fibroblasts or mesothelial cells)
0 - 100% OAW 42
O - 10% stromal cells
El - 30% stromal cells
* - 50% stromal cells
* - 70% stromal cells
- 90% stromal cells
concentrations tested. There was no significant difference in
values from tumours of treated versus untreated patients
with 5-FU, BLM or ADM. There was a trend towards
increased sensitivity to VLB in the treated group (43+28%
vs. 55+34%) and to decreased sensitivity to PM in the
treated group (77+38% vs. 58+35%), although these
differences did not reach significance (Students t test: P=0.2,
P=0.1 respectively).
CIS and MEL
Dose response curves for these drugs tested against human
ovarian tumour cells have not been presented previously
using this assay, and they are shown in Figure 2a,b and
3a,b. Summaries of the data are shown in Table III.
Results obtained when DMSO was tested alone at
dilutions of 1/100, 1/1000 and 1/10,000 showed that the
compound had significant activity against some tumours at a
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Table II Summary of % of control 3H-leucine incorporation for PM, 5-FU, ADM,
BLM and VLB
j*0b
U T
80+ 31 101+44
19-136 64-262
19 0
1.0
U
52+22
16-93
42
U
77+27
33-165
7
0.2
T
51 +30
16-133
54
T
72+32
18-136
9
1.0
U T
69+ 33 64+23
20-174 29-116
32 25
0.1
U
60 +36
15-188
46
T
54+29
14-119
61
0.jb
U T
92+22 115+61
58-162 71-285
0 0
0.1
U
77+24
23-135
12
T
87+42
49-182
8
0.02
U T
87+16 94+36
53-122 45-210
0 0
0.1
U T
81+23 83+20
50-165 44-115
4 12
0.01
U
71+32
17-106
25
T
63+29
20-112
38
aSensitive - <50% of control; bdrug concentration in jgml-1; U = untreated
patients; T=treated patients; PM - 31 U, 19T; 5-FU - 24U, 13T; ADM - 27U,
lIT; BLM - 25U, 16T; VLB - 24U, 13T.
Table III Summary of % of control 3H-leucine incorporation for CIS and MEL
CIS loa 1.oa o.la
U T U T U T
x+s.d. 6+13 11+18 47+23 70+40 83+ 18 101+48
range 1-58 1-73 2-113 10-137 38-128 54-236
% sensitive 97 95 52 37 10 0
MEL 10 1.0 0.1
U T U T U T
x+ s.d. 58+23 65+34 82+24 85+25 95+ 17 90+11
range 11-101 14-143 14-107 42-123 65-121 69-105
% sensitive 33 36 5 9 0 0
aDrug concentration in pgml-P; Sensitive <50% of control; U=untreated patients;
T=treated patients; CIS - 31 U, 19T; MEL - 21 U, lIT.
dilution of 1/100. It was routinely included in 34 assays and
in 26 of these the percentage of control values ranged from
*72-100%, whilst for another 5 tumours (MEL resistant)
there was stimulation to >110% (maximum 281%). For 3
other tumours (MEL sensitive) values of 57%, 44% and
64% were obtained and these have been excluded from the
data presented in Figure 2a,b and summarised in Table III.
No tumours showed marked sensitivity to MEL at
10 pgml- 1, the concentration which elicited greatest
variation between tumours, and, although there was a slight
shift towards resistance in the treated group, this value did
not approach significance.
CIS was routinely tested at 0.1, 1.0 and 1O0gml-l against
50 tumours (31 untreated, 19 treated) (Figure 3a, b) and
additional concentrations were included for 9 tumours
(Figure 4). For both treated and untreated tumours the
widest range of sensitivities was observed at gml- 1 and
the difference between untreated and treated tumours
(47% +23% vs. 70% +40%) was significant (unpaired
Students 't' test, 2P=0.05). Inclusion of additional con-
centrations between 1 and 10 gml-l (Figure 4) did not alter
the relative sensitivity ratings of 8 of the tumours, but one
(40M) did show a marked increase in sensitivity between 1
and 2jgml -1.
Comparison ofin vitro results with clinical outcome to
chemotherapy
Correlations between in vitro results and in vivo response to
treatment were possible in 17 untreated patients and 14
treated patients. Relevant data are presented in Tables IV
and V for each group. Ten untreated patients received CIS
only (Section A in Table IV) and the clinical response rate in
this group was 80%. In the absence of defined response
criteria for this assay, cut-off points for CIS and PM were
chosen to give the highest degree of correlation between in
vitro data and clinical outcome. Accordingly, the following
criteria were used at pgml-
1 of CIS: - sensitive - <40%
of control; intermediate - 41-60% of control; resistant -
>61% of control. There were 5 patients in the sensitive
group (56, 53, 20, 8, 9M) all of whom responded regardless
of tumour burden at the onset of chemotherapy. There were
4 patients in the intermediate group (74, 66, 78, 53-multiple
sites received from 53), 3 of whom responded to treatment.
One of these patients also had sensitive tumour cells (53),
one had a complete pelvic clearance at staging laparotomy
(78) and one was found to have residual disease at second
look laparotomy (66). The non-responder was a stage IV
patient with liver involvement (74). In the resistant group
lob
T
77+38
20-188
21
PM
x+s.d.
range
% sensitive'
5-FU
x+s.d.
range
% sensitive
ADM
x+s.d.
range
% sensitive
BLM
x+s.d.
range
% sensitive
VLB
x+s.d.
range
% sensitive
10
T
30+22
3-73
84
2
T
20+23
1-72
82
10
U
58+ 13
1-128
39
U
29+18
8-51
79
U.
24+27
1-105
78
U
46+31
7-114
56
U
55+34
11-180
50
T
46+24
16-104
56
T
43+28
13-112
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Figure 2 Dose-responses of tumour cells from untreated (A)
and treated (B) patients to melphalan.
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Figure 3 Dose-responses of tumour cells from untreated (A)
and treated (B) patients to cis-platinum.
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Figure 4 Dose-responses of tumour cells from one untreated
patient (41 M) and 9 treated patients to additional concentrations
of CIS between and lO gml-1.
there were 2 patients (65, 26) one of whom responded to
treatment (65) and one of whom had progressive disease
(26). The responder was Figo, stage I and had minimal
residual disease at the onset of chemotherapy, whilst the
patient who progressed was again Stage IV with liver
involvement. In this group of 11 patients in vitro and in vivo
results correlated for 9/11 (89%) patients (8=S/S; 1=S/R;
1 =R/S). Six previously untreated patients received CYM
only (Section B, Table IV). For the purpose of comparison
,of in vitro data with clinical outcome, the following criteria
were used at 10gml-1 of PM: - sensitive - <50% of
control; intermediate - 51-60% of control; resistant -
>61% of control. Accordingly, there were 2 patients in the
sensitive group (9 M, 3 M) both of whom had partial
responses (9M was included in the untreated CYM group
because she had responded to 3 courses of CIS but treatment
had been changed to CYM because of impaired renal
function). There were also 2 patients in each of the
intermediate (34M, 41M) and resistant (62, 11M) groups. In
each of the latter groups there was one partial responder and
one progressive disease. In the intermediate group the patient
with PD was stage IV (34M). In the resistant group the
patient who responded had a mixed homologous
mesenchymal sarcoma of the ovary, a tumour which
contains both sarcomatous and adenocarcinomatous
elements. The cells which grew were obviously bizarre, but
did not stain with HMFG2 and did not show typical
epithelial morphology. They were, therefore, believed to
represent the sarcomatous component of the tumour and
lack of correlation in this instance could be attributed to
histological heterogeneity. For these 6 patients in vitro and in
vivo results correlated in 4/6 cases (3=S/S; 1 =R/R; 1 =S/R;
1 =R/S). Two other patients received mixed chemotherapy
(Section C, Table IV), one of whom was resistant in vitro
and in vivo and failed to respond to treatment (59), and the
other patient had a partial response to CIS/ADM to which
drugs her tumour cells showed intermediate sensitivity and
sensitivity respectively (28M).
In the treated group (Table V) there were 10 patients who
had received CIS at some time; 5 of these had received CIS
only as first line therapy (28, 42, 43, 32M, 40M), one had
received CIS in combination (CAP) (73) and 4 had received
CIS as second-line therapy, either alone (40, 48/89, 25M) or
in combination (30M - CAP). The specimens included ascites
from relapse patients (48/49, 28, 42, 43, 25M, 30M, 32M,
40M) and samples from 2LLs (40, 73). Both the samples
from 2LL were of intermediate sensitivity. Of the two relapse
samples of intermediate sensitivity, one came from a stage
IV patient with progressive disease (28) and the other from a
patient who had a complete response to first-line chemo-
therapy with CIS (42) (see 8 in Table IV). In the resistant
group 43 and 32M both had a PR to first-line chemotherapy
with CIS; 40M had had 13 courses of CIS/ADM and
relapsed whilst receiving chemotherapy; 25M relapsed on
CYM/FU/MTX and failed to respond to CIS and 30M failed
to respond initially to treosulfan and subsequently to CAP.
The tumour cells of one patient showed exquisite sensitivity
to CIS (48/49), although she was in relapse following
treatment with this drug. However, throughout chemo-
therapy ascites had been completely controlled, but there
was subjective evidence of increase in size of a mass in the
Pouch of Douglas leading to cessation of treatment.
Eight patients had received CYM at some time. Two of
these were still sensitive (48/49, 38 who had received low-
dose CYM for 3 months) and 6 were resistant. All of the
resistant group had had some response to treatment with
CYM but had relapsed during treatment.
Comparison ofmultiple sites
More than one tumour sample was tested from each of four
patients. These were 20 (R.ovary and ascites), 40-(rectum,
R.ovary, omentum), 53 (R.ovary, L.ovary, omentum, ascites)
and 59 (L.ovary, R.ovary). For 40 and 59 similar chemo-
sensitivity profiles were obtained for all sites tested. There
were differences between sites for 20 and 53 and dose
response curves are shown in Figure 5 and 6. Cells from the
ascites (20, 53) and omentum (53) were more chemosensitive
than their solid counterparts to some of the drugs which
were tested. Ascitic cells from 20 were much more sensitive
to 5-FU and slightly more sensitive to ADM and PM than
the solid tumour cells. Both populations were of equal
sensitivity to CIS. With 53 the omental and ascitic cells were
markedly more sensitive to ADM, CIS and VLB, and
slightly more sensitive to PM, BLM and 5-FU than cells
from the solid tumours.
Comparison between CIS sensitivity and sensitivity to other
drugs
Table VI shows a comparison between tumours showing
sensitivity or resistance to CIS and the sensitivity of the
same tumours to other drugs. Thus, in the untreated group,
there were 16 CIS-sensitive tumours of which 10 were also
sensitive to PM, whilst only 2/15 tumours which were
resistant to CIS still showed some sensitivity to PM. In the
treated group 4/7 CIS-sensitive tumours were also sensitive
to PM but no CIS-resistant tumours showed sensitivity to
PM. A similar distribution was observed with MEL in the
untreated group, but in the treated group cross-sensitivity
and cross-resistance was less clearly defined. In the untreated
group other drugs which showed a trend towards cross-
sensitivity and cross-resistance with CIS were BLM at
I lgml-1 (6/13 vs. 2/13) and 5-FU at 1 gml-1 (8/14 vs.
2/10). Sensitivity to the higher concentrations of ADM,
BLM, 5-FU and also to VLB was approximately similarly
distributed between CIS sensitivity and resistance. In the
treated group cross-sensitivity and cross-resistance was more
marked for ADM and BLM but was unchanged for 5-FUIn vitro CHEMOSENSITIVITY TO cis-PLATINUM 769
Table IV Correlations between in vitro sensitivity and clinical response in untreated patients
Response
Lab. Disease status In vitro
no. Figo after surgery Chemotherapy Clinical Surgical response Correlation
A
8 III inoperable CIS x 5 CR PR(CR)+ 23+4% S/S
20 III >2cm CIS x 5 CR PR(CR)+ 17+3% S/S
53 CIS x 5 CR PR 54+ 11% I/S
(solid)
27+8% S/S
(ascites)
56 <1 cm CIS x 5 CR CR(+) 36+6% S/S
9M IV GRD CISx3 CYM PR ND 40+4% S/S
(renal failure)
66 III >2cm CIS x 5 CR PR 59+2% I/S
74 IV 4cm lesion CIS x 2 PD - 41+7% I/R
liver invol.
78 III clearance CIS x 5 CR CR 52+6% I/S
26 IV liver invol. CIS PD 65+ 11% R/R
65 I clearance CIS x 5 CR ND 63+8% R/S
B
3M III inoperable CYM x 2 PR (died of 39+18% S/S
coronary)
9M IV GRD CIS x 3 CYM PR stable 48+6% S/S
disease
34M IV GRD<2cm CYM PD ND 55% I/R
41 M III GRD CYM PR ND 56% I/S
62 CYM SD ND 67% R/R
IIM III GRD CYM PR ND 123% R/S
C
59 III GRD>2cm CMB, CYM PD ND PM - 74% R/R
MTX MTX - 76%
CIS - 26%
28 M III GRD CIS, ADM PR ND CIS - 60% R/S
ADM - 7% S/S
Disease status: GRD =gross residual disease; MRD=minimal residual disease; Response: CR=complete
response; PR=partial response; PD =progressive disease; SD =stable disease; Surgical response: (CR)
indicates surgical conversion from PR-+CR. +indicates microscopic disease. ND=not done; Correlation:
CIS: S= <40% of control (sensitive); I=41-60% of control (intermediate); R= >61% of control
(resistant); PM: S = <50% of control (sensitive); I =51-60% of control (intermediate); R= >61% of
control (resistant).
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Figure 5 A comparison of dose-responses of tumour cells- from solid tumour (0 0) and ascites (0--O) of the same
patient (OAW 20). All drug concentrations (horizontal axes) are in ygml
-
. ADM =adriamycin, CIS =cis-platinum;
PM=phosphoramide mustard; 5-FU 5-fluorouracil. Error bars=s.d.
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Table V In vitro response data for treated patients
Lab. Previous
no. chemotherapy In vitro response Comments
48/49 CYM; CIS x 4;
CMB; BLM.
28 CIS; MEL.
40 TREO; CIS.
42 CISx5.
73 CIS; ADM; CYM.
(=CAP x 6).
43 CIS.
25 M CYM, 5-FU, MTX-
relapse. CIS x 3.
30M
32M
(=9M
Table IV)
40M
31M
12M
38
1M
TREO 4/12; CIS;
ADM; CYM (CAP).
CIS x 3; BLM x 3;
CYM.
CIS/ADM; CMB;
MEL.
CYM x 5; MEL.
CYM x 6.
low dose
CYM x 3.
MEL.
CIS-10%, CMB-24%,
PM-20%, BLM-28%.
CIS-46%, MEL-40%.
Right CIS-41%,
TREO-59%.
Omentum CIS-44%,
TREO-67%.
Rectum CIS-50%,
TREO-71%.
CIS-55%.
CIS-43%, PM-64%,
ADM-24%.
CIS-67%.
CIS-175%, PM-188%.
CIS-110%, ADM-35%,
PM-105%.
CIS-91%, BLM-71%,
PM-102%.
CIS-66%, PM-82%,
ADM-62%.
CIS-137%, PM-147%,
MEL-131%.
CYM-63%, (CIS-70%).
PM-48%.
MEL-67%, (CIS-75%).
One year's treatment with
endoxana; pleural effusion and
mass in Pouch of Douglas. 4
courses of CIS given, during
which ascites completely
controlled. Chemotherapy stopped
because increase in size of mass
in Pouch of Douglas.
Progressive disease on first-line
chemotherapy with CIS.
Patient was GRD inoperable;
good response to TREO obtained.
CIS given after relapse but no
evidence ofregression: patient
converted to PR at 2LL.
See Lab. No. 8 in Table IV; some
resistance to CIS developed.
Clinically assessed as CR. 2LL
revealed widespread tumour
deposits.
PR obtained to first-line
chemotherapy with CIS.
Relapsed on CYM/5-FU/MTX.
PD after 3 courses of CIS.
PD on treosulfan after 4/12
treatment; no reponse obtained
to CAP.
Post operative residual disease
with bowel involvement. PR on
CIS/BLM consolidated with CYM
because of renal failure.
17 month survival w/o remission.
Metastatic disease Stage IV.
CIS/ADM x 13; CMB x 1; MEL x 1.
PD on CYM and MEL.
Two months of PR obtained.
2LL after three months on low
dose CYM.
Relapse after two years on
Melphalan.
0.1 1.0 10 0.1 1.0 10 0.01 0.1 1.0
Figure 6 A comparison of dose-responses of tumour cells from 4 sites in the same patient (OAW 53). * = right ovary; 0=left
ovary; * = omentum; El =ascites. All drug concentrations (horizontal axes) are in ugml-1. BLM =bleomycin; VLB =vinblastine.
Error bars, which have been omitted for clarity, were of the same order of magnitude as those shown in Figure 5.
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Table VI Comparison between CIS sensitivity and sensitivity to other drugs
PM MEL ADM BLM 5-FU VLB
Drug concentration loa 10 2.0 0.2 10 1.0 10 1.0 0.1
Untreatedpatients
Sensitive to CIS 10/16b 6/9 13/15 3/15 9/13 6/13 11/14 8/14 7/12
Resistant to CIS 2/15 1/12 8/12 1/12 5/12 2/13 8/10 2/10 5/12
Treatedpatients
Sensitive to CIS 4/7 2/5 6/6 1/6 6/7 2/7 6/7 5/7 4/7
Resistant to CIS 0/12 2/6 3/5 1/5 3/9 2/9 5/6 2/6 5/6
aDrug concentrations are in gml-1; bi.e., 10/16 tumours which were sensitive to CIS were also
sensitive to PM.
with 6/7 CIS-sensitive tumours and 5/6 CIS-resistant
tumours showing sensitivity to 5-FU. With VLB there
appeared to be an association between resistance to CIS and
increased sensitivity to VLB.
Discussion
The results obtained with the microtitration assay confirm
and extend previous findings (Wilson & Neal, 1981), viz. that
it can be used to show variations in the chemosensitivities of
human ovarian tumours which reflect the clinically found
pattern of response to chemotherapy.
The overall success rate with the assay was -40% which
is considerably lower than the 80% success rate which has
been reported by groups using the clonogenic assay (Von
Hoff et al., 1983; Simmonds & McDonald, 1984). However,
the number of drug tests achieved for each successful
monolayer culture exceeds that which is normally possible
for the clonogenic assay. Poor growth in monolayer and/or
non-adherence of tumour cells contributed, in part, to the
reduced success rate, but recent data describing the use of
extracellular matrix to improve the monolayer growth of
human ovarian tumour cells (Baker et al., 1986) indicates
that the number of successful cultures may be improved by
appropriate modification of culture conditions. Stromal cell
overgrowth was also a problem and the necessity for
adequate cell identification cannot be over-emphasised.
Whilst there appeared to be no interaction in monolayer
between stromal cells (fibroblasts and mesothelial cells) and
tumour cells with the particular cell line used, in that
increasing numbers of drug-resistant stromal cells produced
a proportional decrease in drug sensitivity of the total mixed
population (see Figure la,b), the possibility that this may
occur with other tumour cells cannot be excluded. The
degree of stromal cell contamination (from 0-30%) did not
influence the presence or absence of positive correlation in
those tumour cultures for which in vivo and in vitro data was
available, which indicates that this is an acceptable stromal
contamination level for primary cultures.
The comparatively low levels of cell kill which were
achieved with both PM and MEL perhaps reflects the short
duration of the assay, which does not permit expression of
delayed cytotoxicity (Freshney et al., 1975). Certainly, higher
levels of cell kill are achieved in the clonogenic assay with
only a one hour exposure. The predictive accuracy of the
microtitration assay may be improved with modifications
permitting the use of a longer recovery period. Recent data
also indicates that PM is an inappropriate metabolite of
CYM to use for in vitro testing and that 4-hydroperoxy-
cyclophosphamide is more relevant (Powers & Sladek, 1983).
The high levels of leucine and glutamine which are present in
growth medium are likely to impair the uptake of MEL
(Vistica et al., 1981) thus providing a further possible
explanation for the low levels of cell kill in monolayer assay,
contrasting with the clonogenic assay in which drug exposure
is usually carried out in a balanced salt solution.
Although tumour cells displayed a greater sensitivity to
CIS than they did to either PM or MEL, this was achieved
at higher concentrations of CIS than those used in the
clonogenic assays, which, taken in conjunction with the long
drug exposure time, indicates reduced sensitivity of the
monolayer assay. Although the theoretical difference in
exposure time is 47h, the actual difference is much less than
this due to the instability of the drug solution. Pre-
incubation of drug solutions has shown that there is a
measurable decrease in activity of CIS by 12h (6% of
control compared with 23% of control at 1ugml-1) and
that activity is completely lost by 48h (Wilson, unpublished
data). The short recovery period also contributes to the
reduced sensitivity of the assay and a prolonged recovery
period of 12 days has also been shown to enhance the
sensitivity of the assay (Wilson, unpublished data). In the
monolayer assay described here 39% of all tumours tested
were very sensitive to CIS (<40% of control) and 71%
showed some sensitivity (<60% of control). These values
are very similar to those reported by Simmonds and
McDonald (1984) for CIS sensitivity (48% sensitive, 79%
intermediate +sensitive). Thus, in spite of their intrinsic
differences the monolayer and clonogenic assays are
predicting similar response rates of primary ovarian
carcinoma cells to CIS.
Correlation between in vitro sensitivity and clinical
outcome in untreated patients was positive in 9/11 patients
(8 =S/S; 1=R/R) (89%). Correlation with extreme sensitivity
to CIS (<40% of control) was very good with no false
positives. The overall response rate was very high, however,
since patients were previously untreated and received
aggressive first-line chemotherapy. This contrasts with other
studies in which patients have either been heavily pretreated
or receiving a wide range of drugs. On the basis of the
argument first put forward by Berenbaum (1974) a random
prediction of 70% in vitro sensitivity in a patient group with
an 80% response rate would give an overall positive
correlation rate of 58% (56% =S/S; 2% =R/R), a value
which is far exceeded by the 89% correlation rate obtained.
The intermediate group presented a different picture,
however, and there is some evidence to suggest that tumour
burden plays an important role in the clinical outcome of
this group. Patients with MRD were disease-free on
completion of chemotherapy (-6 months) and, although it
could be argued that there was no macroscopic disease
present when chemotherapy was started, microscopic disease
could be expected to have been present which, in the resistant
or untreated patient, is likely to have manifested itself as
gross disease in the 6 months following laparotomy. The
observation that no stage IV patients with liver involvement
and intermediate sensitivity tumours showed a clinical
response provides the converse argument.
In vitro survival of >60% of control correlated well with
clinical resistance in the treated group of patients. A finding
of particular interest was the low level of resistance shown
by tumour cells from patients who had received CIS and
responded. Thus, tumours from patients 42, 43, and 73772 A.P. WILSON et al.
showed values of 55%, 67% and 43% of control
respectively, and 48/49 had cells which were very sensitive to
CIS (< 10% of control). All of these patients had had some
response to CIS and, although one would not expect such a
high level of sensitivity in 48/49, ascites in this patient was
completely controlled whilst she was receiving the drug. In
view of the difference in chemosensitivity exhibited by solid
vs. ascitic tumour cells, the apparent lack of correlation may
be attributable to this factor.
Extreme resistance to CIS (75% - 1 M; 175% - 25M; 110%
- 30M; 137% - 31 M; 91% - 32M) was seen only in some of
the heavily pre-treated Manchester patients. The finding that
tumours from responding patients who had received CIS
showed lower levels of resistance either immediately after
completion of chemotherapy or on relapse, suggests that
high-dose CIS as first-line therapy does not induce extreme
chemoresistance. This contrasts with the previously used
palliative chemotherapy which invariably led to clinical
resistance since therapy was continued to the point of relapse
rather than to the point of limiting toxicity as is the case
with CIS. There is clinical data to support the view that
responses can be obtained following first-line therapy with
CIS. Ozolls et al. (1987) reported that second-line responses
to carboplatin could be obtained in patients who had
responded to CIS and Sessa (1986) has shown that patients
who responded to CIS could have a second response to
iproplatin.
Comparison of in vitro sensitivity to CIS with in vitro
sensitivity to other drugs showed that sensitivity to CIS did
occur in the absence of cross-sensitivity to either PM or
MEL. Sensitivity to PM or MEL and resistance to CIS was
an infrequent occurrence. The absence of cross-sensitivity
and cross-resistance for the high concentrations of ADM,
BLM and 5-FU vs. CIS in the untreated group argues for
the use of these drugs in combination with CIS. The
increased incidence of cross-resistance to ADM and BLM in
the treated group probably reflects the fact that these drugs
were included in the chemotherapy which many patients
received. The finding that cross-resistance to 5-FU did not
develop in the treated group is of particular interest. The
efficacy of this drug in the treatment of epithelial ovarian
cancer has recently been demonstrated (Ozolls et al., 1984)
and it also has the advantage that it can be administered i.p.
to achieve high therapeutic concentrations. The increased
sensitivity to VLB which was found in treated patients
reflects a similar observation made by Alberts (Alberts et al.,
1980) using the clonogenic assay. Unfortunately clinical
application of this in vitro finding has not produced the
expected response (Kavanagh et al., 1984).
With the advent of effective combination chemotherapy
regimens for the treatment of ovarian cancer the role of in
vitro sensitivity testing in this disease is less clearly defined.
In the past one of the main functions of predictive testing
seems to have been to confirm resistance in the heavily pre-
treated patient. This was of little therapeutic benefit since
resistance to the majority of available drugs was already
present. From the findings of the present study it is
suggested that the assay could be of benefit in the following
situations: (1) for stage IV patients who are likely to achieve
a response to CIS if the tumour shows extreme in vitro
sensitivity; (2) for patients with impaired renal function or
other reasons for dose-reduction or chemotherapy other than
CIS; (3) extreme in vitro sensitivity to CIS in untreated
patients' tumours who subsequently receive the drug,
respond and later relapse may be a good prognostic
indication for obtaining a second-line response.
It is concluded that the microtitration assay provides in
vitro information on the drug sensitivity of ovarian tumour
cells which parallels the clinical response rates obtained with
CIS and also those to be expected with single agent chemo-
therapy using other drugs (Wilson & Neal, 1981). With the
increasing interest in the use of human tumour cell lines and
primary cultures for screening new compounds the assay
could be of use in this context.
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